drugset / Trial / NCT02406014

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

NCT02406014

Phase 4 Completed 502 enrolled LEO Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 4, multi-centre, randomized, two group, open label, active controlled, parallel group, 17 week trial.

Timeline

Start
2015-04
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diclofenac Other / unclassified 3 % Topical
Comparator Diclofenac Other / unclassified 0.5 g Topical
Comparator ingenol mebutate Small molecule 0.015 % Topical

Indications